Kết quả tìm kiếm

Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy participants Bằng Robert Shumaker, Jagadeesh Aluri, Jean Fan, Gresel Martinez, Gary A. Thompson, Min Ren

lấy văn bản lấy văn bản

Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development Bằng Qingyang Gu, Bin Zhang, Hongye Sun, Qiang Xu, Yexiong Tan, Guan Wang, Qin Luo, Weiguo Xu, Shuqun Yang, Jian Li, Jing Fu, Lei Chen, Shengxian Yuan, Gui‐Bai Liang, Qunsheng Ji, Shuhui Chen, Chi-Chung Chan, Weiping Zhou, Xiaowei Xu, Hongyang Wang, Douglas D. Fang

lấy văn bản lấy văn bản

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment Bằng Maria E. Cabanillas, Martin Schlumberger, Barbara Jarząb, Renato Martins, Furio Pacini, Bruce Robinson, Judith C. McCaffrey, Manisha H. Shah, Donald Bodenner, Duncan J. Topliss, Corina Andresen, James P. O’Brien, Min Ren, Yasuhiro Funahashi, Roger Allison, Rossella Elisei, Kate Newbold, Lisa Licitra, Steven I. Sherman, Douglas W. Ball

lấy văn bản

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma Bằng Masafumi Ikeda, Takuji Okusaka, Shuichi Mitsunaga, Hideki Ueno, Toshiyuki Tamai, Takuya Suzuki, Seiichi Hayato, Tadashi Kadowaki, Kiwamu Okita, Hiromitsu Kumada

lấy văn bản

New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions Bằng Makoto Chuma, Katsumi Terashita, Naoya Sakamoto

lấy văn bản lấy văn bản

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer Bằng Naomi Kiyota, Martin Schlumberger, Kei Muro, Yukio Ando, Shunji Takahashi, Yasukazu Kawai, Lori J. Wirth, Bruce Robinson, Steven I. Sherman, Takuya Suzuki, Katsuki Fujino, Anubha Gupta, Seiichi Hayato, Makoto Tahara

lấy văn bản lấy văn bản

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer Bằng Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G. Gianoukakis, Naomi Kiyota, Matthew H. Taylor, Sung‐Bae Kim, Monika K. Krzyzanowska, Corina E. Dutcus, Begoña de las Heras, Junming Zhu, Steven I. Sherman

lấy văn bản lấy văn bản

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer Bằng Martin Schlumberger, Barbara Jarząb, Maria E. Cabanillas, Bruce Robinson, Furio Pacini, Douglas W. Ball, Judith C. McCaffrey, Kate Newbold, Roger Allison, Renato Martins, Lisa Licitra, Manisha H. Shah, Donald Bodenner, Rossella Elisei, Lynn A. Burmeister, Yasuhiro Funahashi, Min Ren, James P. O'Brien, Steven I. Sherman

lấy văn bản

Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization Bằng Kiyoshi Okamoto, Megumi Ikemori‐Kawada, A. Jestel, Konstanze von König, Yasuhiro Funahashi, Tomohiro Matsushima, Akihiko Tsuruoka, Atsushi Inoue, Junji Matsui

lấy văn bản

Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications Bằng Catherine Frenette

lấy văn bản

Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options Bằng Francesco Perri

lấy văn bản

Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults Bằng Robert Shumaker, Jagadeesh Aluri, Jean Fan, Gresel Martinez, Gary A. Thompson, Min Ren

lấy văn bản lấy văn bản

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Bằng Jaume Capdevila, Neda Stjepanovic

lấy văn bản lấy văn bản

Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions Bằng Furio Pacini, Yasuhiro Ito, Markus Luster, Fabián Pitoia, Bruce Robinson, Lori J. Wirth

lấy văn bản lấy văn bản

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models Bằng Kiyoshi Okamoto, Kotaro Kodama, Kazuma Takase, Naoko Hata Sugi, Yuji Yamamoto, Masao Iwata, Akihiko Tsuruoka

lấy văn bản

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models Bằng Osamu Tohyama, Junji Matsui, Kotaro Kodama, Naoko Hata-Sugi, Takayuki Kimura, Kiyoshi Okamoto, Yukinori Minoshima, Masao Iwata, Yasuhiro Funahashi

lấy văn bản lấy văn bản

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC) Bằng Ana M. Molina, Thomas E. Hutson, James Larkin, Anne Gold, Karen Wood, Dave Carter, Robert J. Motzer, M. Dror Michaelson

lấy văn bản lấy văn bản

Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodine-Refractory Patients Bằng Joshua J. Gruber, A. Dimitrios Colevas

lấy văn bản

Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective Bằng Marcia S. Brose, Catherine Frenette, Stephen J. O’Keefe, Stacey Stein

lấy văn bản

Influence of hepatic impairment on lenvatinib pharmacokinetics following single‐dose oral administration Bằng Robert Shumaker, Jagadeesh Aluri, Jean Fan, Gresel Martinez, Helen S. Pentikis, Min Ren

lấy văn bản lấy văn bản